直肠癌新辅助放化疗后显微镜下壁内播散研究
本研究分析54例直肠癌患者新辅助放化疗后TME标本,测量残余肿瘤的显微镜下壁内播散(MIS)。69%患者无MIS,ycT1-2与ycT3-4患者MIS发生率分别为22%和36%,ypT1-2患者均无MIS。结论提示多数患者无MIS,肿瘤厚度对选择接触近距离放疗患者至关重要。
要点
- 69%直肠癌患者新辅助放化疗后无显微镜下壁内播散。
- ycT1-2与ycT3-4患者MIS发生率分别为22%和36%。
- ypT1-2患者均未观察到MIS。
核心结论
- 69%的直肠癌患者在新辅助治疗后不保留显微镜下壁内播散。
- 了解肿瘤厚度对于选择接触近距离放疗(CXB)患者似乎至关重要。
研究设计与样本
- 分析2016至2022年Maastricht大学医学中心(MUMC+)的直肠癌患者队列。
- 患者放疗后六周接受MRI、CT和乙状结肠镜检查,随后手术。
- 对TME标本进行病理分析,包括全层大蜡块,测量残余宏观肿瘤和MIS。
主要发现
- 54例患者中37例(69%)无MIS。
- ycT1-2肿瘤患者中4/18(22%)观察到MIS,ycT3-4肿瘤患者中13/36(36%)观察到MIS。
- 4例患者(7%)显示连续性MIS,15例(28%)显示碎片状MIS。
- ypT1-2患者均无MIS。
临床怎么用
- 新辅助放化疗后多数直肠癌患者无MIS,提示部分患者可能无需额外治疗边缘。
- 肿瘤厚度信息可用于筛选适合接触近距离放疗(CXB)或局部切除的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigates microscopic intramural spread (MIS) after neoadjuvant (chemo)radiotherapy on Total Mesorectal Excision (TME) specimens of rectal cancer patients and explores the necessity of an additional treatment margin for endorectal radiation boosts (for example through contact brachytherapy (CXB)) or local excisions. METHODS: A cohort of patients from Maastricht University Medical Center (MUMC + ) treated between 2016 and 2022 was analyzed. Patients underwent MRI, CT scans, and sigmoidoscopy six weeks after radiotherapy, followed by surgery. Pathological analysis of TME specimens, including whole mount macro-cassettes, was performed to measure residual macroscopic tumor and MIS. Fragmented and continuous MIS were recorded parallel and perpendicular to the bowel wall. RESULTS: Out of 54 patients, 37 (69%) exhibited no MIS. MIS was observed in 4/18 (22%) of patients with ycT1-2 tumors and 13/36 (36%) of patients with ycT3-4 tumors. 4 patients (7%) showed continuous MIS and 15 (28%) showed fragmented MIS. No patients with ypT1-2 had MIS. CONCLUSIONS: 69% of patients do not retain MIS post-neoadjuvant therapy. Knowledge of tumor thickness seems crucial for patient selection for CXB.
引用
- Verrijssen AE, Van Limbergen EJ, Bellezzo M, et al. Microscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation. Clin Transl Radiat Oncol. 2025. PMID: 40851780. doi:10.1016/j.ctro.2025.100963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。